Literature DB >> 20303008

VEGFA +936C>T polymorphism and cancer risk: a meta-analysis.

Bin Xu1, Jiu-Ming Li, Na Tong, Jun Tao, Peng-Chao Li, Ning-Hong Song, Wei Zhang, Hong-Fei Wu, Ning-Han Feng, Li-Xin Hua.   

Abstract

Vascular endothelial growth factor A (VEGF-A), a major driver of physiological and pathological angiogenesis, plays important roles in the etiology and metastasis of cancers. The +936C>T polymorphism in the 3'-untranslated region of the VEGFA gene has been implicated in cancer risk and is related to VEGF-A protein production; however, published data have been conflicting. To derive a more precise estimation of the relationship, a meta-analysis was performed of 13,293 cancer cases and 12,308 control subjects from 29 published case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between +936C>T polymorphism and cancer risk. The meta-analysis indicated that individuals with the +936 T had increased risk of oral cancer (OR = 1.39, 95% CI = 1.03-1.88), although no association was found in the contrast of T versus C (OR = 1.00, 95% CI = 0.91-1.10) in the pooled analyses. This meta-analysis supports the idea that VEGFA + 936 T is associated with increased risk of oral cancer. To draw comprehensive and true conclusions, further prospective studies with larger numbers of participants worldwide are needed to examine associations between VEGFA + 936C>T polymorphism and cancer risk. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303008     DOI: 10.1016/j.cancergencyto.2009.11.007

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  Polymorphism of vascular endothelial growth factor -1154G>A (rs1570360) with cancer risk: a meta-analysis of 16 case-control studies.

Authors:  Ting-Ting Hong; Ru-Xia Zhang; Xiao-Hong Wu; Dong Hua
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

2.  Vascular endothelial growth factor (VEGF) gene polymorphisms and risk of head and neck cancer: a meta-analysis involving 2,444 individuals.

Authors:  Wei-Dong Leng; Mei-Ni He; Qi-Lin Chen; Heng Gong; Li Zhang; Xian-Tao Zeng
Journal:  Mol Biol Rep       Date:  2013-09-21       Impact factor: 2.316

3.  Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies.

Authors:  Liu Liu; Lin Liu; Fei Zeng; Kai Wang; Jun Huang; Lin Xin; Pei-Qian Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-21       Impact factor: 4.553

4.  Polymorphisms in the 5'- and 3'-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics.

Authors:  Cristiane Oliveira; Gustavo J Lourenço; Priscilla M R Silva; Cassio Cardoso-Filho; Maira H C Favarelli; Neiva S L Gonçales; Maria S C Gurgel; Carmen S P Lima
Journal:  Tumour Biol       Date:  2010-10-28

5.  Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study.

Authors:  Alicia Beeghly-Fadiel; Xiao-Ou Shu; Wei Lu; Jirong Long; Qiuyin Cai; Yong-Bing Xiang; Ying Zheng; Zhongming Zhao; Kai Gu; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-11-30       Impact factor: 4.254

6.  C936T polymorphism of the VEGF gene in relation to the risk and the clinical and biological characteristics of sporadic colorectal adenocarcinoma.

Authors:  Laura Credidio; Carmen Silvia Passos Lima; Raquel Leal; Maria Lourdes S de Ayrizono; João José Fagundes; Luis Alberto Magna; Claudio Saddy Rodrigues Coy
Journal:  BMC Res Notes       Date:  2014-10-31

7.  Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.

Authors:  Zoi Lanara; Efstathia Giannopoulou; Marta Fullen; Evangelos Kostantinopoulos; Jean-Christophe Nebel; Haralabos P Kalofonos; George P Patrinos; Cristiana Pavlidis
Journal:  Hum Genomics       Date:  2013-06-05       Impact factor: 4.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.